GLYCO-ENGINEERED INTERLEUKIN-4 BASED ANTAGONISTS
The present invention relates to IL-4 muteins capable of inhibiting IL-4 and/or IL-13 signalling, wherein a non-protein-polymer is conjugated to the mutein via a mutated amino acid, which allows site-directed conjugation of a non-protein polymer. The present invention further relates to nucleic acid...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The present invention relates to IL-4 muteins capable of inhibiting IL-4 and/or IL-13 signalling, wherein a non-protein-polymer is conjugated to the mutein via a mutated amino acid, which allows site-directed conjugation of a non-protein polymer. The present invention further relates to nucleic acids and vectors encoding the IL-4 muteins as well as pharmaceutical compositions, kit of parts comprising the IL-4 muteins. The invention further relates to the IL-4 muteins for use in methods of treatment. |
|---|